Scancell Holdings (GB:SCLP) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Scancell Holdings has reported a successful year with its lead cancer vaccine SCIB1 showing promising results in a Phase 2 trial for melanoma, exceeding the 70% objective response rate target, while also progressing with its Modi-1 vaccine and securing strategic partnerships. The company’s financial position remains solid with an operating loss of £18.3 million, a cash balance of £14.8 million, and a cash runway extending into the third quarter of 2025. Key organizational appointments have been made, positioning Scancell for pivotal studies and further development in the coming years.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.